LOGIN
Early Denosumab vs. Ibandronate in Intertrochanteric Fracture Healing: A Randomized Comparison
March 2025
Early Denosumab vs. Ibandronate in Intertrochanteric Fracture Healing: A Randomized Comparison
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Does early administration of denosumab delay bone healing after intertrochanteric femoral fractures?
J Orthop Sci. 2025 Jan;30(1):136-141.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Sixty-six patients with intertrochanteric femoral fragility fractures were randomized to receive either denosumab (DSM) (n=33) or ibandronate (IBN) (n=33) within one week postoperatively. The primary outcome was radiological fracture healing at three months, assessed via plain radiographs and computed tomography (CT). Secondary outcomes included clinical healing, pain on loading, and walking abili...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.